Wêrom Medysk Ûndersyk troch de Farmaseutyske Yndustry Finansierd Wurdt
June 7, 2026 · Frisian News
Pharmaceutical companies fund roughly 60 percent of clinical trials in the United States, creating a fundamental conflict of interest. Trials funded by drug makers are three to five times more likely to reach conclusions favoring the sponsor's product than independent research.
FryskFarmaseutyske bedriuwen finansierje sawat 60 persint fan 'e klinyske ûndersiken yn de Feriene Steaten. Dit makket in foar de hân lizzend probleem: de yndustry betellet foar it measte ûndersyk dat oantoant dat har eigen produkten wurkje. Ûnôfhinklik ûndersyk bestiet wol, mar it is seldsemer en minder sichtber as troch de yndustry sponsore stúdzjes dy't geunstiche resultaten opsmite.
De sifers binne dúdlik. Ûndersiken finansierd troch farma-bedriuwen hawwe trije oant fiif kear mear kâns op konklúzjes dy't geunstich binne foar it produkt fan 'e sponsor as ûndersiken finansierd troch de regearing of non-profits. De beynfloeding is net altyd ûnearlik, it is struktureel. Ûndersikers witte hokker bedriuw de rekken betelle hat.
It probleem giet fierder as yndividuele stúdzjes. Farmaseutyske bedriuwen kieze hokker medisinen ûndersocht wurde, net regeringen of ûnôfhinklike ûndersikers. Djoere patintearre genêsmiddelen krije hûnderten ûndersiken. Goedkeape generyske drugs dy't wurkje mar gjin winst opsmite, krije hast gjin omtinken. Kankerpasjinten kinne in tosyn behannelinge yn detail ûndersocht sjen, wylst liders fan seldseme sykten hast neat hawwe.
Medyske tydskriften en universiteiten bewearje dit konflikt te kontrôlearjen. Se publisearje ferklearringen fan belangeferstrengeling en rjochtlinen foar redakteuren. Dan publisearje se deselde troch de yndustry finansierde stúdzjes dochs, om't dy abonnees en reklame-ynkomsten lûke. De poartewachters profitearje fan de poarte dy't se sizze te hoedzjen.
Dokters skriuwe foar op basis fan wat it ûndersyk seit. Pasjinten fertrouje har dokters. Gjin fan beide groepen freget wa't de rekken betelle hat. Oant dy fraach rûtine wurdt, sille farmaseutyske bedriuwen it bewiismateriaal dat har produkten rjochtfeardiget, besitte.
Pharmaceutical companies fund roughly 60 percent of clinical trials in the United States. This creates an obvious problem: the industry pays for most of the research that claims to prove its own products work. Independent research exists, but it is rarer and less visible than industry-sponsored studies that find favorable results.
The numbers are stark. Trials funded by drug makers are between three and five times more likely to reach conclusions favoring the sponsor's product than trials funded by government or nonprofits. The bias is not always dishonest, it is structural. Researchers know which company signed the check.
The problem goes beyond individual studies. Pharmaceutical companies choose which drugs to study, not governments or independent researchers. Expensive patented medicines get hundreds of trials. Cheap generic drugs that work but generate no profit get almost none. Cancer patients may have a dozen treatment options studied in detail, while rare disease sufferers have almost nothing.
Medical journals and universities claim to police this conflict. They publish conflict-of-interest statements and editorial guidelines. Then they publish the same industry-funded research anyway, because it attracts subscribers and advertising revenue. The institutions that are supposed to be gatekeepers profit from the gate they claim to guard.
Doctors prescribe based on what the research says. Patients trust their doctors. Neither group asks who wrote the check. Until that question becomes routine, pharmaceutical companies will own the evidence base that justifies their products.
Published June 7, 2026 · Frisian News · Ljouwert, Fryslân